|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen K, Yang D, Li X, Sun B, Song F, Cao
W, Brat DJ, Gao Z, Li H, Liang H, et al: Mutational landscape of
gastric adenocarcinoma in Chinese: Implications for prognosis and
therapy. Proc Natl Acad Sci USA. 112:1107–1112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim C, Mulder K and Spratlin J: How
prognostic and predictive biomarkers are transforming our
understanding and management of advanced gastric cancer.
Oncologist. 19:1046–1055. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park J, Yoo HM, Jang W, Shin S, Kim M, Kim
Y, Lee SW and Kim JG: Distribution of somatic mutations of
cancer-related genes according to microsatellite instability status
in Korean gastric cancer. Medicine (Baltimore). 96:e72242017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jaiswal BS, Kljavin NM, Stawiski EW, Chan
E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar
KA, et al: Oncogenic ERBB3 mutations in human cancers. Cancer Cell.
23:603–617. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bang YJ, Im SA, Lee KW, Cho JY, Song EK,
Lee KH, Kim YH, Park JO, Chun HG, Zang DY, et al: Randomized,
double-blind phase II trial with prospective classification by ATM
protein level to evaluate the efficacy and tolerability of olaparib
plus paclitaxel in patients with recurrent or metastatic gastric
cancer. J Clin Oncol. 33:3858–3865. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SY, Ahn T, Bang H, Ham JS, Kim J, Kim
ST, Jang J, Shim M, Kang SY, Park SH, et al: Acquired resistance to
LY2874455 in FGFR2-amplified gastric cancer through an emergence of
novel FGFR2-ACSL5 fusion. Oncotarget. 8:15014–15022.
2017.PubMed/NCBI
|
|
12
|
Lennerz JK, Kwak EL, Ackerman A, Michael
M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD,
Haber DA, et al: MET amplification identifies a small and
aggressive subgroup of esophagogastric adenocarcinoma with evidence
of responsiveness to crizotinib. J Clin Oncol. 29:4803–4810. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuboki Y, Yamashita S, Niwa T, Ushijima T,
Nagatsuma A, Kuwata T, Yoshino T, Doi T, Ochiai A and Ohtsu A:
Comprehensive analyses using next-generation sequencing and
immunohistochemistry enable precise treatment in advanced gastric
cancer. Ann Oncol. 27:127–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Flicek P, Amode MR, Barrell D, Beal K,
Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G,
Fitzgerald S, et al: Ensembl 2014. Nucleic Acids Res. 42:D749–D755.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cingolani P, Platts A, Wang le L, Coon M,
Nguyen T, Wang L, Land SJ, Lu X and Ruden DM: A program for
annotating and predicting the effects of single nucleotide
polymorphisms, SnpEff: SNPs in the genome of drosophila
melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 6:80–92.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gospodarowicz MK, Brierley JD and
Wittekind C: TNM classification of malignant tumoursJohn Wiley
& Sons; 2017
|
|
17
|
Nakamura K, Sugano H and Takagi K:
Carcinoma of the stomach in incipient phase: Its histogenesis and
histological appearances. Gan. 59:251–258. 1968.PubMed/NCBI
|
|
18
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Talos F and Moll UM: Role of the p53
family in stabilizing the genome and preventing polyploidization.
Adv Exp Med Biol. 676:73–91. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ronowicz A, Janaszak-Jasiecka A, Skokowski
J, Madanecki P, Bartoszewski R, Balut M, Seroczynska B, Kochan K,
Bogdan A, Butkus M, et al: Concurrent DNA copy-number alterations
and mutations in genes related to maintenance of genome stability
in uninvolved mammary glandular tissue from breast cancer patients.
Hum Mutat. 36:1088–1099. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fische M: Census and evaluation of p53
target genes. Oncogene. 36:3943–3956. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bartlett JD, Close GL, Drust B and Morton
JP: The emerging role of p53 in exercise metabolism. Sports Med.
44:303–309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bellazzo A, Sicari D, Valentino E, Del Sal
G and Collavin L: Complexes formed by mutant p53 and their roles in
breast cancer. Breast cancer (Dove Med Press). 10:101–112.
2018.PubMed/NCBI
|
|
24
|
Katona BW and Rustgi AK: Gastric cancer
genomics: Advances and future directions. Cell Mol Gastroenterol
Hepatol. 3:211–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spano JP, Milano G, Vignot S and Khayat D:
Potential predictive markers of response to EGFR-targeted therapies
in colorectal cancer. Crit Rev Oncol Hematol. 66:21–30. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Raponi M, Winkler H and Dracopoli NC: KRAS
mutations predict response to EGFR inhibitors. Curr Opin Pharmacol.
8:413–418. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Waddell T, Chau I, Cunningham D, Gonzalez
D, Okines AFC, Wotherspoon A, Saffery C, Middleton G, Wadsley J,
Ferry D, et al: Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lordick F, Kang YK, Chung HC, Salman P, Oh
SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et
al: Capecitabine and cisplatin with or without cetuximab for
patients with previously untreated advanced gastric cancer
(EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shen Y, Han X, Wang J, Wang S, Yang H, Lu
S-H and Shi Y: Prognostic impact of mutation profiling in patients
with stage II and III colon cancer. Sci Rep. 6:243102016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hankey W, Frankel WL and Groden J:
Functions of the APC tumor suppressor protein dependent and
independent of canonical WNT signaling: Implications for
therapeutic targeting. Cancer Metastasis Rev. 37:159–172. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aoki K and Taketo MM: Adenomatous
polyposis coli (APC): A multi-functional tumor suppressor gene. J
Cell Sci. 120:3327–3335. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rubinfeld B, Souza B, Albert I, Müller O,
Chamberlain SH, Masiarz FR, Munemitsu S and Polakis P: Association
of the APC gene product with beta-catenin. Science. 262:1731–1734.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Su LK, Vogelstein B and Kinzler KW:
Association of the APC tumor suppressor protein with catenins.
Science. 262:1734–1737. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lv XP: Gastrointestinal tract cancers:
Genetics, heritability and germ line mutations. Oncol Lett.
13:1499–1508. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ajani JA, Lee J, Sano T, Janjigian YY, Fan
D and Song S: Gastric adenocarcinoma. Nature Rev Dis Primers.
3:170362017. View Article : Google Scholar
|
|
36
|
Wang JY, Hsieh JS, Chen CC, Tzou WS, Cheng
TL, Chen FM, Huang TJ, Huang YS, Huang SY, Yang T and Lin SR:
Alterations of APC, c-met, and p53 genes in tumor tissue and serum
of patients with gastric cancers. J Surg Res. 120:242–248. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ghatak S, Chakraborty P, Sarkar SR,
Chowdhury B, Bhaumik A and Kumar NS: Novel APC gene mutations
associated with protein alteration in diffuse type gastric cancer.
BMC Med Genet. 18:612017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sato M, Kojima M, Nagatsuma AK, Nakamura
Y, Saito N and Ochiai A: Optimal fixation for total preanalytic
phase evaluation in pathology laboratories: A comprehensive study
including immunohistochemistry, DNA, and mRNA assays. Pathol Int.
64:209–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen X, Deane NG, Lewis KB, Li J, Zhu J,
Washington MK and Beauchamp RD: Comparison of Nanostring
nCounter® data on FFPE colon cancer samples and
affymetrix microarray data on matched frozen tissues. PLoS One.
11:e01537842016. View Article : Google Scholar : PubMed/NCBI
|
